The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Associate Professor Sophia Zackrisson, MD, PhD. Photo.

Sophia Zackrisson

Manager

Associate Professor Sophia Zackrisson, MD, PhD. Photo.

Population-based Organised Prostate Cancer Testing : Results from the First Invitation of 50-year-old Men

Author

  • Ola Bratt
  • Rebecka Arnsrud Godtman
  • Thomas Jiborn
  • Jonas Wallström
  • Olof Akre
  • Stefan Carlsson
  • Tobias Nordström
  • Erik Thimansson
  • Max Alterbeck
  • Sophia Zackrisson
  • Jonas Hugosson
  • Anders Bjartell
  • Anna Lantz
Show all

Summary, in English

Background: The European Union recently recommended evaluation of the feasibility of organised prostate cancer screening. In Sweden, regional population-based organised prostate cancer testing (OPT) programmes were introduced in 2020. Objective: To describe initial participation rates and diagnostic outcomes. Design, setting, and participants: The three most populated Swedish regions invited all men aged 50 yr to OPT by a letter in 2020–2022. Men with prostate-specific antigen (PSA) ≥3 ng/ml were referred for prostate magnetic resonance imaging (MRI). PSA assays differed across regions. Men with Prostate Imaging Reporting and Data System (PI-RADS) 1–3 and PSA density ≥0.15 ng/ml/cm3 or PI-RADS 4–5 were referred for a biopsy. Data were obtained from the Swedish Register for Organised Prostate Cancer Testing. Outcome measurements and statistical analysis: Overall and regional participation rates, PSA distributions, PI-RADS score distributions, cancer detection, and treatment were evaluated. Results and limitations: A total of 23 855 (35%) of 68 060 invited men participated; 696 (2.9%) had PSA ≥3 ng/ml, and of them, 306 (44%) had a biopsy indication and 221 (32%) had a biopsy. On biopsy, 93 (42%) had Gleason grade group ≥2 (0.39% of PSA-tested men) and 44 (20%) Gleason grade group 1 cancer. Most men with cancer had treatment with curative intent (70%) or were under active surveillance (28%). Across regions, proportions of men with PSA ≥3 ng/ml ranged from 2.3% to 4.0%, and those with PI-RADS score 4–5 ranged from 12% to 21%. A limitation is that results are applicable only to first testing of men in their early 50s. Conclusions: The OPT programmes are feasible with good compliance to the diagnostic pathway. The use of MRI and PSA density avoided a biopsy for over half of the men with PSA ≥3 ng/ml. Inter-regional differences in diagnostic outcomes show a need for standardisation of the diagnostic pathway's components. Patient summary: We report the diagnostic outcomes of inviting 68 000 50-yr-old men to organised prostate cancer testing.

Department/s

  • Urological cancer, Malmö
  • Radiology Diagnostics, Malmö
  • LUCC: Lund University Cancer Centre
  • EpiHealth: Epidemiology for Health
  • LTH Profile Area: Photon Science and Technology
  • LU Profile Area: Light and Materials
  • Division of Translational Cancer Research

Publishing year

2024-03

Language

English

Pages

207-214

Publication/Series

European Urology

Volume

85

Issue

3

Document type

Journal article

Publisher

Elsevier

Topic

  • Cancer and Oncology

Keywords

  • Early detection
  • Population
  • Prostate cancer
  • Prostate-specific antigen
  • Screening

Status

Published

Research group

  • Urological cancer, Malmö
  • Radiology Diagnostics, Malmö

ISBN/ISSN/Other

  • ISSN: 0302-2838